TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31756181

Group type: EXPERIMENTAL
Intervention: Zone distance varianceGLDZM
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Zone distance varianceGLDZM threshold of 1.70
Number of subjects: 213
Study: 29117336

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin treatment
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using OV28 questionnaire
Number of subjects: 454

Group type: COMPARATOR
Intervention: Clinician-reported neuropathy
Number of subjects: 454

Group type: COMPARATOR
Intervention: Older age, bevacizumab treatment, bowel resection
Number of subjects: 454

Group type: COMPARATOR
Intervention: Older age, volume of residual disease
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: MAPT additive polymorphisms
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: GSK3B additive polymorphisms
Number of subjects: 454
Study: 25414157

Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotic therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: 12 weeks of antibiotic therapy
Number of subjects: 40
Study: 24432669

Group type: EXPERIMENTAL
Intervention: Bushen Qiangji Decoction (BQD) or Qingre Qiangji Decoction (QQD)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Sulfasalazine enteric‐coated tablet (SECT)
Number of subjects: 354
Study: 22900440

Group type: EXPERIMENTAL
Intervention: Xylitol treatment (chewing gum for mothers and tablets for children, consumed three times/day for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xylitol treatment (experimental group)
Number of subjects: 60
Study: 20183464

Group type: EXPERIMENTAL
Intervention: Mixed effects model for repeated measurements (MMRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted generalized estimating equations (GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unweighted generalized estimating equations (GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-imputation-based GEE (MI-GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete case (CC) analysis of covariance (ANCOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF) ANCOVA
Number of subjects: 0
Study: 17166358

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (infusion of insulin if blood glucose >6.1 mmol/L, maintenance at 4.4‐6.1 mmol/L)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional treatment (infusion of insulin if blood glucose >11.9 mmol/L, maintenance at 10.0‐11.1 mmol/L)
Number of subjects: 116
Study: 15284112

Group type: EXPERIMENTAL
Intervention: R-FCM (rituximab + FCM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: FCM (fludarabine, cyclophosphamide, mitoxantrone)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: R-FCM
Number of subjects: 147
Study: 11388528

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 60
Study: 9413892

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil gel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Optiderm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Xylocain ointment 5%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-pretreated skin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alloknesis
Number of subjects: 12
Study: 8214944

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) pretreatment (30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-steroid treatment (Control)
Number of subjects: 0
Study: 3658289

Group type: EXPERIMENTAL
Intervention: Second-look laparotomy after comprehensive surgical staging and randomization into clinical protocols
Number of subjects: 112
Study: 31115739

Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training (TIMT) for 12 weeks, 30–45 min/day, 5 days/week
Number of subjects: 16
Study: 31880807

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 28372309

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study: 25256795

Group type: EXPERIMENTAL
Intervention: Implementation intention (II) intervention with narrative healthy snacking scenarios
Number of subjects: 148

Group type: COMPARATOR
Intervention: Implementation intention (II) intervention without narrative healthy snacking scenarios
Number of subjects: 148
Study: 23356790

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, and 70 mg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 21666396

Group type: EXPERIMENTAL
Intervention: Glow gel hand washing without hand hygiene education
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glow gel hand washing with hand hygiene education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 60
Study: 18443512

Group type: EXPERIMENTAL
Intervention: Surgical treatment for chronic postoperative groin pain
Number of subjects: 19

Group type: COMPARATOR
Intervention: Preoperative pain
Number of subjects: 19

Group type: COMPARATOR
Intervention: Postoperative pain
Number of subjects: 19
Study: 17163237

Group type: EXPERIMENTAL
Intervention: Alendronic acid 70 mg weekly
Number of subjects: 936

Group type: COMPARATOR
Intervention: Risedronic acid 35 mg weekly
Number of subjects: 936
Study: 12544936

Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 360
Study: 10498386

Group type: EXPERIMENTAL
Intervention: Standard medical care
Number of subjects: 2416
Study: 8888353

Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FO+E)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 2069096

Group type: EXPERIMENTAL
Intervention: Tebufelone 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tebufelone 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tebufelone 200 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tebufelone 25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 650 mg ASA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7049154

Group type: EXPERIMENTAL
Intervention: Copper 7 200 (Cu 7 200)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiload Copper 250 (ML Cu 250)
Number of subjects: 0
Study: 31322739

Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously every 3 weeks over 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg
Number of subjects: 0
Study: 30496705

Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation (235 mg/day anthocyanins)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation
Number of subjects: 12
Study: 29391271

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA-FFA) 500 mg, twice daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28760225

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 24515505

Group type: EXPERIMENTAL
Intervention: Children with parent-reported ASD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents of children with ASD
Number of subjects: 0
Study: 23028703

Group type: EXPERIMENTAL
Intervention: Audio‐based Environment Simulator (AbES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal directed gaming strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AbES
Number of subjects: 0
Study: 20026571

Group type: EXPERIMENTAL
Intervention: Exercise and education schemes held twice weekly for eight weeks
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 243
Study: 16973901

Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immobilization in tension using a below-knee cast with the ankle in a neutral position for 6 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 11300442

Group type: EXPERIMENTAL
Intervention: Abciximab (bolus 0.25 mg/kg body weight, infusion 10 microg per min for 12 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tirofiban (bolus 10 microg/kg, infusion 0.15 microg/kg per min for 72 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus 180 microg/kg, infusion 2 microg/kg per min for 72 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 60
Study: 9275887

Group type: EXPERIMENTAL
Intervention: Sonographically guided technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anatomic landmark technique
Number of subjects: 100
Study: 8093127

Group type: EXPERIMENTAL
Intervention: Technetium 99m nanocolloid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Indium 111 leucocytes
Number of subjects: 19
Study: 3522528

Group type: EXPERIMENTAL
Intervention: Timentin (3 g/200 mg injections)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Cefamandole (0.75 g injections)
Number of subjects: 484
Study: 31609301

Group type: EXPERIMENTAL
Intervention: L-Tyrosine (150 mg·kg)
Number of subjects: 9
Study: 29498933

Group type: EXPERIMENTAL
Intervention: myo-inositol + folic acid (4000 mg myo-inositol + 400 μg folic acid per day)
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: myo-inositol + folic acid
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 3602

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3602
Study: 26905565

Group type: EXPERIMENTAL
Intervention: MD-Knee (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium hyaluronate (Group B)
Number of subjects: 60
Study: 25659187

Group type: EXPERIMENTAL
Intervention: Ziprasidone monotherapy for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 6 weeks followed by ziprasidone for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 120
Study: 23101474

Group type: EXPERIMENTAL
Intervention: Twin and Sibling sample
Number of subjects: 377000

Group type: EXPERIMENTAL
Intervention: Shared environment factors
Number of subjects: 377000

Group type: EXPERIMENTAL
Intervention: Behavioral variation factors
Number of subjects: 377000
Study: 20692693

Group type: EXPERIMENTAL
Intervention: PRB28 (peginterferon alfa‐2b, ribavirin, and boceprevir 800 mg three times a day for 28 weeks)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: PR4/PRB24 (peginterferon alfa‐2b and ribavirin for 4 weeks, followed by peginterferon alfa‐2b, ribavirin, and boceprevir for 24 weeks)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: PRB48 (peginterferon alfa‐2b, ribavirin, and boceprevir for 48 weeks)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: PR4/PRB44 (peginterferon alfa‐2b, ribavirin, and boceprevir for 44 weeks)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: low-dose PRB48 (low-dose ribavirin plus peginterferon alfa‐2b and boceprevir for 48 weeks)
Number of subjects: 520

Group type: COMPARATOR
Intervention: PR48 (peginterferon alfa‐2b and ribavirin for 48 weeks)
Number of subjects: 520
Study: 18379219

Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (4 sets, 10 repetitions, 90 s rest at 75% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strength protocol (11 sets, 3 repetitions, 5 min rest at 90% 1RM)
Number of subjects: 10
Study: 16777271

Group type: EXPERIMENTAL
Intervention: Immune modulating jejunostomy feeding (Stresson-Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard isonitrogenous, isocaloric feed (Nutrison High Protein-Group B)
Number of subjects: 120
Study: 12666038

Group type: EXPERIMENTAL
Intervention: Perinatal factors including miscarriage symptoms, premature delivery symptoms, severe flu attacks, tobacco abuse, alcohol abuse, minor congenital malformations, neonatal seizures, and hospitalizations during newborn period.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Premature delivery symptoms, severe flu attacks, and neonatal seizures (identified through stepwise logistic multiple regression analysis).
Number of subjects: 200
Study: 11009262

Group type: EXPERIMENTAL
Intervention: Coronary stenting in ESRD patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Coronary stenting in control group (non-ESRD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall mortality in ESRD patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overall mortality in control group (non-ESRD)
Number of subjects: 34
Study: 8774326

Group type: EXPERIMENTAL
Intervention: Progressive, supervised aerobic walking programme for 52 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 21
Study: 1612374

Group type: EXPERIMENTAL
Intervention: Consultation/Endoscopy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 66
Study: 30074007

Group type: EXPERIMENTAL
Intervention: Ketac Molar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photac Fil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dyract XP
Number of subjects: 30
Study: 26854486

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.25 mg/kg/day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Isotretinoin and Placebo
Number of subjects: 156
Study: 24156269

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 303
Study: 22906061

Group type: EXPERIMENTAL
Intervention: Pain coping skills training
Number of subjects: 402

Group type: COMPARATOR
Intervention: Arthritis education control
Number of subjects: 402

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 402
Study: 20524999

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (0.066 mg/kg, max 4 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Zoledronic acid and Placebo
Number of subjects: 13
Study: 17768587

Group type: EXPERIMENTAL
Intervention: Physical training (three fast 30-minute walks and two sessions of one-hour training per week)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sensitivity intention to treat analysis
Number of subjects: 112
Study: 16624969

Group type: EXPERIMENTAL
Intervention: Sunscreen use 1 or 2 days per week
Number of subjects: 139

Group type: COMPARATOR
Intervention: Sunscreen use daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Time spent outdoors
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 139
Study: 12654707

Group type: EXPERIMENTAL
Intervention: Candesartan (800 microg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Candesartan (800 microg/min) + Icatibant (90 microg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Candesartan (800 microg/min) + L-NMMA (7 micromol/min)
Number of subjects: 20
Study: 10919416

Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg x kg(‐1) bolus over 15 min, followed by 10 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (equal volume bolus followed by placebo infusion)
Number of subjects: 234
Study: 8979280

Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5% eye drops administered 3 times daily as adjunctive therapy to timolol 0.5% eye drops twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Timolol 0.5% eye drops alone
Number of subjects: 16
Study: 1461951

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 676
Study: 6723452

Group type: EXPERIMENTAL
Intervention: Home-based intervention program focusing on modeling verbal interaction between mother and child around selected toys and books
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Variation with toys and books supplied without home visits
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (comparison treatments)
Number of subjects: 4
Study: 31562406

Group type: EXPERIMENTAL
Intervention: Short tailored alcohol-related advice tool and leaflet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mouth cancer prevention leaflet only (Control)
Number of subjects: 12
Study: 30387335

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) after surgical excision and radiotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Surgical excision and radiotherapy only (Control group)
Number of subjects: 240
Study: 27339806

Group type: EXPERIMENTAL
Intervention: 1 mg folic acid, 25 mg Vitamin B6, and Vitamin B12
Number of subjects: 300
Study: 24365797

Group type: EXPERIMENTAL
Intervention: COH-IVF
Number of subjects: 194

Group type: COMPARATOR
Intervention: MNC-IVF
Number of subjects: 194

Group type: COMPARATOR
Intervention: Sub-NC
Number of subjects: 194
Study: 22152083

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) walking with elastic knee wraps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON) walking without blood flow restriction
Number of subjects: 0
Study: 20625068

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (30 micrograms once weekly for 2 years)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (once weekly for 2 years)
Number of subjects: 160
Study: 18565107

Group type: EXPERIMENTAL
Intervention: Levetiracetam (3000 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15731564

Group type: EXPERIMENTAL
Intervention: Superflux cellulose triacetate (CTA; Tricea 150G)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Low-flux polysulfone (PS; F 6HPS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: High-flux PS (F 60S)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Superflux PS (F 500S)
Number of subjects: 4
Study: 11791150

Group type: EXPERIMENTAL
Intervention: Oral administration of sucrose (2160 kJ, 575 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of maltose (2160 kJ, 575 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water control (67 kJ, 575 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intragastric infusion of sucrose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intragastric infusion of maltose
Number of subjects: 6
Study: 9935120

Group type: EXPERIMENTAL
Intervention: Hamilton Thorne Research integrated visual optical system semen analyzers
Number of subjects: 30
Study: 8534464

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intrathecal normal saline (control)
Number of subjects: 15
Study: 2178534

Group type: EXPERIMENTAL
Intervention: 1 mg of warfarin, beginning 3 days before catheter insertion and continuing for 90 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: No warfarin
Number of subjects: 121
Study: 6988929

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31272930

Group type: EXPERIMENTAL
Intervention: Semaglutide once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28479118

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25434633

Group type: EXPERIMENTAL
Intervention: Vascular catheter insertion for management of malignant ascites
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vascular catheter insertion for management of lymphocysts
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vascular catheter for patients with chronic ascites
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vascular catheter for patients before primary cytoreduction for ovarian cancer
Number of subjects: 55
Study: 23580599

Group type: EXPERIMENTAL
Intervention: High-intensity isometric resistance training for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 14
Study: 21258206

Group type: EXPERIMENTAL
Intervention: Combination therapy with percutaneous microwave ablation (PMWA) and adoptive immunotherapy
Number of subjects: 10
Study: 19751500

Group type: EXPERIMENTAL
Intervention: Information program with specific procedural, sensory and coping information about their ICU stay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trivial conversation without any ICU‐specific information
Number of subjects: 0
Study: 17331963

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg/day
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study: 16371870

Group type: EXPERIMENTAL
Intervention: MMR Berna vaccine
Number of subjects: 467

Group type: COMPARATOR
Intervention: Licensed vaccine M-M-R-Vax (Merck & Co.)
Number of subjects: 467
Study: 12526191

Group type: EXPERIMENTAL
Intervention: Bovine-derived bone protein extract with 12.5 micrograms/mg DFDBA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bovine-derived bone protein extract with 25.0 micrograms/mg DFDBA
Number of subjects: 25
Study: 9594863

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) at 40 ppm added to the oxygenator sweep gas
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no NO treatment)
Number of subjects: 20